Published in Drug News Perspect on September 01, 2009
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer | NCT00365599
Decitabine in Treating Patients With Advanced Solid Tumors | NCT00030615
Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol Cancer Res (2011) 0.87
The TCF4/β-catenin pathway and chromatin structure cooperate to regulate D-glucuronyl C5-epimerase expression in breast cancer. Epigenetics (2012) 0.81
Cancer control and prevention by nutrition and epigenetic approaches. Antioxid Redox Signal (2012) 0.79
Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer. Oncotarget (2016) 0.75
Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation. Oncotarget (2017) 0.75
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. Diseases (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
The language of covalent histone modifications. Nature (2000) 44.92
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (1995) 11.53
miR-21-mediated tumor growth. Oncogene (2006) 9.90
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (1997) 9.71
A decade of molecular biology of retinoic acid receptors. FASEB J (1996) 9.70
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06
Perceptions of epigenetics. Nature (2007) 8.43
NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol Cell (1998) 7.58
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem (2001) 6.85
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell (2005) 6.00
Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell (1997) 5.83
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet (2000) 5.72
Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet (1999) 5.70
DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet (2000) 5.09
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem (2008) 4.56
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet (2005) 4.33
SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature (2008) 4.27
The inheritance of epigenetic defects. Science (1987) 4.15
Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science (2006) 3.87
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature (2000) 3.78
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol (2007) 3.39
DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet (2002) 3.25
Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3.25
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res (1994) 3.18
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol (2008) 3.18
DNA methylation and breast carcinogenesis. Oncogene (2002) 3.03
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol (2002) 3.00
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97
Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol (2001) 2.91
Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res (1998) 2.83
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer (2006) 2.74
High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A (2000) 2.70
Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res (2005) 2.67
Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol (1998) 2.64
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res (2001) 2.50
MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene (2006) 2.47
Estrogen activates telomerase. Cancer Res (1999) 2.41
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol (2007) 2.39
Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst (2004) 2.37
Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell (2008) 2.35
Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol (2005) 2.34
Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res (2004) 2.29
Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene (1998) 2.28
Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst (2000) 2.25
BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell (2002) 2.24
Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J (2003) 2.21
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res (2000) 2.18
Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res (2001) 2.18
Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res (2004) 2.17
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res (1999) 2.17
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer (2008) 2.13
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res (2001) 2.08
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene (2002) 2.02
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A (1999) 2.00
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res (2000) 1.98
Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem (2003) 1.98
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res (2004) 1.97
Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res (2001) 1.95
Hsp90: a novel target for cancer therapy. Curr Top Med Chem (2006) 1.93
HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci U S A (2001) 1.89
Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene (2001) 1.89
Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther (2003) 1.88
Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res (1998) 1.81
Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res (2005) 1.80
Genome-wide mapping and characterization of hypomethylated sites in human tissues and breast cancer cell lines. Genome Res (2008) 1.79
Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res (1997) 1.79
DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res (1999) 1.79
Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res (1996) 1.77
Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med (1995) 1.76
Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008) 1.75
CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res (2000) 1.73
Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression. J Biol Chem (2003) 1.71
Identification of eight proteins that cross-link to pre-mRNA in the yeast commitment complex. Genes Dev (1999) 1.71
MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br J Cancer (2003) 1.71
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res (2000) 1.70
Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist (2006) 1.70
Breast cancer metastasis: a microRNA story. Breast Cancer Res (2008) 1.70
Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol (2002) 1.68
Lumbar epidural morphine in humans and supraspinal analgesia to experimental heat pain. Anesthesiology (2000) 1.67
LMA-Supreme--a new single-use LMA with gastric access: a report on its clinical efficacy. Br J Anaesth (2008) 1.44
Pharmacodynamics of orally administered sustained- release hydromorphone in humans. Anesthesiology (2001) 1.09